To get a number reading of a CD3+/CD8+ T cell Breast Immunoscore using immunofluorescence (QIF) in posttreatment FFPE tumor biopsy samples collected on day 14-21 of C1 of Pembrolizumab.

Have you been diagnosed with cancer or a benign disease that is being evaluated for cancer for which you may receive treatment? If so, you may be able to take part in a research study that collects biospecimens (e.g. blood, saliva, tissue, etc) and health information to better understand how cancers develop and affect the body,]. If so, you may be able to take part in a research study that aims to identify non-invasive biomarkers for cervical cancer screening and monitoring following treatment of abnormal areas on the cervix caused by HPV.

This is a research study for people diagnosed MDS or AML. The purpose of this study is to see if the study drug SL-172154, works better alone or in combination azacitidine or with azacitidine and venetoclax.

The purpose of this study is to understand how monitoring symptoms at home after lung cancer diagnosis could impact quality of care and the likelihood of returning to the hospital. This study will also help us understand whether symptom monitoring in patients with advanced lung cancer is helpful for patients and the clinical teams who care for them.

Have you been diagnosed with pleural fluid, and have been referred for a pleural fluid drainage? If so, you may be able to participate in a research registry to help us learn more about lung cancer.

Have you been diagnosed with Advanced Prostate Cancer? If so, you may be able to take part in an International Registry for Men.

Have you ever been diagnosed with metastatic triple negative breast cancer and received 2 or less lines of chemotherapy for your metastatic disease? If so you may be eligible for a trial to evaluate different treatment combination with avelumab for your metastatic breast cancer.

Have you ever been diagnosed with HER2 positive metastatic breast cancer and had disease progression after receiving at least one type of therapy? If so you may be eligible for a clinical trial that tests niraparib in combination with trastuzumab.

Have you been diagnosed with HER-2 positive breast cancer and have already received treatment with chemotherapy followed by surgery? Was your breast cancer still present at time of surgery and removed? If so you may be eligible for a trial to see if a combination of T-DM1 with tucatinib is better than receiving T-DM1 alone at preventing your cancer from returning.

Have you been diagnosed with relapsed or refractory multiple myeloma? If so, you may be able to take part in a research study looking at the safety and effectiveness of giving a combination of treatments to patients with relapsed or refractory multiple myeloma who are toxicity-vulnerable.